Erectile Dysfunction Drugs (MCP-6161) - Global Industry Analysts, Inc.

Research Abstract

This report analyzes the worldwide markets for Erectile Dysfunction Drugs in US$ Million. The report provides separate comprehensive analytics for US, Canada, Japan, Europe,and Rest of the World. Annual estimates and forecasts are provided for each region for the period 2007 through 2015. Also, a six-year historic analysis is provided for these markets. The report profiles 26 companies including many key and niche players worldwide such as Abbott Laboratories, Eli Lilly and Company, Inc., F. Hoffmann-La Roche, Inc., GlaxoSmithKline plc, Nexmed, Inc., Pfizer, Inc., Sanofi-aventis SA, Vivus, Inc., and Warner Chilcott Limited. Market data and analytics are derived from primary and secondary research. Company profiles are primarily based upon search engine sources in the public domain.

Code :	MCP-6161
Price :	$3950
Companies :	26

Pages :	391
Date :	April 2010
Market Data Tables :	145

Complimentary Market Brief:

Request a Complimentary Copy of the Report Insights, Key Findings, Drivers, Trends, Program Sources, and Methodology.

ERECTILE DYSFUNCTION DRUGS (Complete Report)

Pages : 391

$3950

I. INTRODUCTION, METHODOLOGY & PRODUCT DEFINITION

$295

Study Reliability and Reporting Limitations.....I-1

Disclaimers.....I-2

Data Interpretation & Reporting Level.....I-3

Quantitative Techniques & Analytics.....I-3

Product Definitions and Scope of Study.....I-3

II. EXECUTIVE SUMMARY

$2250

1. INDUSTRY OVERVIEW.....II-1

$295

Market Scenario.....II-1

Current & Future Analysis.....II-1

Challenges.....II-1

$120

Opportunity for Novel Therapies.....II-2

Competitive Scenario.....II-2

Major Drugs.....II-2

Viagra (sildenafil).....II-2

$120

Cialis (tadalafil).....II-3

Levitra (vardenafil hydrochloride).....II-3

Comparative Analysis.....II-3

Similarities.....II-3

Differences.....II-3

Side Effects.....II-3

$120

2. PRODUCT OVERVIEW.....II-4

$950

Introduction.....II-4

Erectile Dysfunction.....II-4

Pathophysiology.....II-4

$120

Causes.....II-5

Symptoms.....II-5

$120

Diagnosis.....II-6

Medical Diagnosis.....II-6

Patient History.....II-6

Physical Examination.....II-6

Laboratory Tests.....II-6

$120

Other Tests.....II-7

Psychosocial Examination.....II-7

Clinical Tests.....II-7

Duplex Ultrasound.....II-7

Bulbocavernosus Reflex Test.....II-7

Nocturnal Penile Tumescence.....II-7

Penile Biothesiometry.....II-7

$120

Penile Angiogram.....II-8

Corpus Cavernosometry.....II-8

Digital Subtraction Angiography (DSA).....II-8

Magnetic Resonance Angiography.....II-8

Treatment.....II-8

Overview.....II-8

$120

Psychotherapy.....II-9

Behavioral Changes.....II-9

Stop Smoking.....II-9

Control Cholesterol.....II-9

Reduction in Fat.....II-9

$120

Oral Treatment.....II-10

Drug Therapy.....II-10

Other Non-Invasive Treatments.....II-10

$120

Vacuum Constriction Device.....II-11

Minimal Invasive Therapies.....II-11

Surgery.....II-11

Penile Prostheses.....II-11

$120

Arterial Surgery.....II-12

Venous Surgery.....II-12

Latest Advancements in Treatments.....II-12

$120

Future Medications for Treatment of Erectile Dysfunction.....II-13

Alprostadil.....II-13

Apomorphine.....II-13

Meloncortin Stimulators.....II-13

Gene Therapy.....II-13

Unapproved and Controversial Treatments.....II-13

Naltrexone.....II-13

Bremelanotide.....II-13

$120

Melanotan II.....II-14

hMaxi-K.....II-14

Enzyte.....II-14

Prelox.....II-14

Yohimbe.....II-14

Natural Remedies.....II-14

$120

L-Arginine.....II-15

Ginkgo.....II-15

Ginseng.....II-15

Ashwagandha.....II-15

Cordiceps Sinensis.....II-15

$120

Horny Goat Weed.....II-16

Chinese Angelica.....II-16

Pomegranate Juice.....II-16

$120

3. RECENT INDUSTRY ACTIVITY.....II-17

Warner Chilcott Inks Agreement with Dong-A PharmTech.....II-17

Warner Chilcott Signs Agreement with NexMed.....II-17

Coloplast Establishes US Headquarters.....II-17

Vivus Commences Phase-III Trials of Avanafil.....II-17

$120

Skreem Entertainment Inks Letter of Intent to Purchase EdMed.....II-18

Eli Lilly Receives FDA Approval for Cialis®.....II-18

Eli Lilly Partners with Sanofi-Aventis.....II-18

Deerfield Management Collaborates with Vivus.....II-18

Eli Lilly Purchases ICOS.....II-18

$120

4. FOCUS ON SELECT PLAYERS.....II-19

$295

Abbott Laboratories (US).....II-19

Eli Lilly and Company, Inc. (US).....II-19

F. Hoffmann-La Roche, Inc. (US).....II-19

GlaxoSmithKline plc (UK).....II-19

$120

Nexmed, Inc. (US).....II-20

Pfizer, Inc. (US).....II-20

Sanofi-aventis SA (France).....II-20

Vivus, Inc. (US).....II-20

$120

Warner Chilcott Limited (US).....II-21

$120

5. GLOBAL MARKET PERSPECTIVE.....II-22

Table 1: World Recent Past, Current & Future Analysis for Erectile Dysfunction Drugs by Geographic Region – US, Canada, Japan, Europe, and Rest of World Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2007 through 2015 (includes corresponding Graph/Chart).....II-22

$300

Table 2: World Historic Review for Erectile Dysfunction Drugs by Geographic Region – US, Canada, Japan, Europe, and Rest of World Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2001 through 2006 (includes corresponding Graph/Chart).....II-23

$300

Table 3: World 13-Year Perspective for Erectile Dysfunction Drugs by Geographic Region – Percentage Breakdown of Dollar Sales for US, Canada, Japan, Europe, and Rest of World Markets for Years 2003, 2009 & 2015 (includes corresponding Graph/Chart).....II-24

$300

III. MARKET

$1950

1. THE UNITED STATES.....III-1

$595

A. Market Analysis.....III-1

Current & Future Analysis.....III-1

ED Market Witnesses Robust Demand.....III-1

User Base Expands with Better Understanding of Disease Indications.....III-1

Lower Market Penetration Offers Growth Opportunities.....III-1

$100

Lack of Insurance Coverage Affects ED Drug Sales.....III-2

Strategic Corporate Developments.....III-2

$200

Select Players.....III-4

Abbott Laboratories.....III-4

Eli Lilly and Company, Inc......III-4

F. Hoffmann-La Roche, Inc......III-4

$100

Nexmed, Inc......III-5

Pfizer, Inc......III-5

Vivus, Inc......III-5

Warner Chilcott Limited.....III-5

$100

B. Market Analytics.....III-6

Table 4: US Recent Past, Current and Future Analysis for Erectile Dysfunction Drugs Analyzed with Annual Sales Figures in US$ Million for Years 2007 through 2015 (includes corresponding Graph/Chart).....III-6

Table 5: US Historic Review for Erectile Dysfunction Drugs Analyzed with Annual Sales Figures in US$ Million for Years 2001 through 2006 (includes corresponding Graph/Chart).....III-6

$150

2. CANADA.....III-7

Market Analysis.....III-7

Table 6: Canadian Recent Past, Current and Future Analysis for Erectile Dysfunction Drugs Analyzed with Annual Sales Figures in US$ Million for Years 2007 through 2015 (includes corresponding Graph/Chart).....III-7

Table 7: Canadian Historic Review for Erectile Dysfunction Drugs Analyzed with Annual Sales Figures in US$ Million for Years 2001 through 2006 (includes corresponding Graph/Chart).....III-7

$150

3. JAPAN.....III-8

Market Analysis.....III-8

Table 8: Japanese Recent Past, Current and Future Analysis for Erectile Dysfunction Drugs Analyzed with Annual Sales Figures in US$ Million for Years 2007 through 2015 (includes corresponding Graph/Chart).....III-8

Table 9: Japanese Historic Review for Erectile Dysfunction Drugs Analyzed with Annual Sales Figures in US$ Million for Years 2001 through 2006 (includes corresponding Graph/Chart).....III-8

$150

4. EUROPE.....III-9

$495

A. Market Analysis.....III-9

Current & Future Analysis.....III-9

Market for Erectile Dysfunction Products to Rise.....III-9

Development of Novel Drugs for ED and Lifestyle Disorders.....III-9

$100

B. Market Analytics.....III-10

Table 10: European Recent Past, Current and Future Analysis for Erectile Dysfunction Drugs by Geographic Region – France, Germany, Italy, UK, and Rest of Europe Independently Analyzed with Annual Sales Figures in US$ Million for Years 2007 through 2015 (includes corresponding Graph/Chart).....III-10

$150

Table 11: European Historic Review for Erectile Dysfunction Drugs by Geographic Region – France, Germany, Italy, UK, and Rest of Europe Independently Analyzed with Annual Sales Figures in US$ Million for Years 2001 through 2006 (includes corresponding Graph/Chart).....III-11

$150

Table 12: European 13-Year Perspective for Erectile Dysfunction Drugs by Country/Region – Percentage Breakdown of Dollar Sales for France, Germany, Italy, UK, and Rest of Europe Markets for Years 2003, 2009 and 2015.....III-12

$150

4a. FRANCE.....III-13

$295

A. Market Analysis.....III-13

Current & Future Analysis.....III-13

Sanofi-Aventis SA – A Major French Player.....III-13

B. Market Analytics.....III-13

Table 13: French Recent Past, Current and Future Analysis for Erectile Dysfunction Drugs Analyzed with Annual Sales Figures in US$ Million for Years 2007 through 2015 (includes corresponding Graph/Chart).....III-13

$150

Table 14: French Historic Review for Erectile Dysfunction Drugs Analyzed with Annual Sales Figures in US$ Million for Years 2001 through 2006 (includes corresponding Graph/Chart).....III-14

$150

4b. GERMANY.....III-15

Market Analysis.....III-15

Table 15: German Recent Past, Current and Future Analysis for Erectile Dysfunction Drugs Analyzed with Annual Sales Figures in US$ Million for Years 2007 through 2015 (includes corresponding Graph/Chart).....III-15

Table 16: German Historic Review for Erectile Dysfunction Drugs Analyzed with Annual Sales Figures in US$ Million for Years 2001 through 2006 (includes corresponding Graph/Chart).....III-15

$150

4c. ITALY.....III-16

Market Analysis.....III-16

Table 17: Italian Recent Past, Current and Future Analysis for Erectile Dysfunction Drugs Analyzed with Annual Sales Figures in US$ Million for Years 2007 through 2015 (includes corresponding Graph/Chart).....III-16

Table 18: Italian Historic Review for Erectile Dysfunction Drugs Analyzed with Annual Sales Figures in US$ Million for Years 2001 through 2006 (includes corresponding Graph/Chart).....III-16

$150

4d. THE UNITED KINGDOM.....III-17

$295

A. Market Analysis.....III-17

Current & Future Analysis.....III-17

GlaxoSmithKline plc – A Major UK Player.....III-17

B. Market Analytics.....III-17

Table 19: UK Recent Past, Current and Future Analysis for Erectile Dysfunction Drugs Analyzed with Annual Sales Figures in US$ Million for Years 2007 through 2015 (includes corresponding Graph/Chart).....III-17

$150

Table 20: UK Historic Review for Erectile Dysfunction Drugs Analyzed with Annual Sales Figures in US$ Million for Years 2001 through 2006 (includes corresponding Graph/Chart).....III-18

$150

4e. REST OF EUROPE.....III-19

$295

A. Market Analysis.....III-19

Current & Future Analysis.....III-19

Strategic Corporate Development.....III-19

B. Market Analytics.....III-19

Table 21: Rest of Europe Recent Past, Current and Future Analysis for Erectile Dysfunction Drugs Analyzed with Annual Sales Figures in US$ Million for Years 2007 through 2015 (includes corresponding Graph/Chart).....III-19

$150

Table 22: Rest of Europe Historic Review for Erectile Dysfunction Drugs Analyzed with Annual Sales Figures in US$ Million for Years 2001 through 2006 (includes corresponding Graph/Chart).....III-20

$150

5. REST OF WORLD.....III-21

$295

Market Analysis.....III-21

Table 23: Rest of World Recent Past, Current and Future Analysis for Erectile Dysfunction Drugs Analyzed with Annual Sales Figures in US$ Million for Years 2007 through 2015 (includes corresponding Graph/Chart).....III-21

$150

Table 24: Rest of World Historic Review for Erectile Dysfunction Drugs Analyzed with Annual Sales Figures in US$ Million for Years 2001 through 2006 (includes corresponding Graph/Chart).....III-22

$150

IV. COMPETITIVE LANDSCAPE

332

$995

Total Companies Profiled: 26 (including Divisions/Subsidiaries - 30)
Region/Country                 Players

The United States                 15
Japan                              3
Europe                             9
     France                        1
     Germany                       1
     The United Kingdom            2
     Rest of Europe                5
Asia-Pacific (Excluding Japan)     2
Middle East                        1

Click here to request a full table of contents and more details on this project.

ERECTILE DYSFUNCTION DRUGS - A GLOBAL STRATEGIC BUSINESS REPORT

Research Abstract

Complimentary Market Brief:

TABLE OF CONTENTS

ERECTILE DYSFUNCTION DRUGS - A GLOBAL STRATEGIC BUSINESS REPORT stLight.options({ publisher:'12345' });

Research Abstract

Complimentary Market Brief:

TABLE OF CONTENTS

ERECTILE DYSFUNCTION DRUGS - A GLOBAL STRATEGIC BUSINESS REPORT